BRAF and melanoma: Vemurafenib was the first selective oral BRAF small molecule inhibitor, approved in 2011 by the FDA, for advanced melanoma treatment and in 2013 a second selective BRAF inhibitor, Dabrafenib, was approved by the FDA (2, 39).